Document link: MEDICINES RECOMMENDED FOR MINOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) Document Preview:
Call for Proposals for 2021 and 2022 AHEAD-HPSR Research Priorities
The Philippine Council for Health Research and Development and the Department of Health are inviting you to the Call for Proposals for 2021 and 2022 AHEAD-HPSR research priorities. Priority topics for 2021 are as follows: 1. Evaluation of the National Objectives for Health 2017 – 2022 2. Evidence Review of COVID-19 Health Technology Topics ( continue reading : Call for Proposals for 2021 and 2022 AHEAD-HPSR Research Priorities
HTAC recommends COVID-19 Vaccine AstraZeneca under emergency use for reducing COVID-19 risk in persons aged 18 and older
COVID-19 Vaccine AstraZeneca under emergency use can reduce risk against COVID-19 for priority groups aged 18 and older, HTAC notes in a recent recommendation. How it works: COVID-19 Vaccine AstraZeneca COVID-19 Vaccine AstraZeneca uses a weakened common cold virus (called adenovirus) as carrier of the instructions for our cells to make the “spike protein” unique continue reading : HTAC recommends COVID-19 Vaccine AstraZeneca under emergency use for reducing COVID-19 risk in persons aged 18 and older
COVID-19 Vaccine AstraZeneca Guidance for Health Care Providers
The HTAC recommends the emergency use of the AstraZeneca COVID-19 Vaccine to prevent COVID-19 for persons aged 18 and older within identified priority groups. COVID-19 Vaccine (ChAdOx1-S [recombinant]) (COVID-19 Vaccine AstraZeneca) under emergency use The Food and Drug Administration (FDA) issues emergency use authorization (EUA) for unregistered vaccines and drugs during public health emergencies. This continue reading : COVID-19 Vaccine AstraZeneca Guidance for Health Care Providers